Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2198 - Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates


09 Oct 2016


Poster display


Elaine Kilgour


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


E. Kilgour1, H. Angell2, N.R. Smith3, M. Ahdesmaki2, J.C. Barrett4, E.A. Harrington2, C. Hurst5, M.A. Knowles5

Author affiliations

  • 1 Oncology Translational Science, AstraZeneca, SK10 4TG - Macclesfield/GB
  • 2 Oncology Translational Science, AstraZeneca, Cambridge/GB
  • 3 Oncology Translational Science, AstraZeneca, Macclesfield/GB
  • 4 Oncology Translational Science, AstraZeneca, Boston/US
  • 5 Institute Of Cancer And Pathology, University of Leeds, Leeds/GB


Abstract 2198


Activating FGFR3 mutations occur in about 15% MIBC and 70% non-MIBC (NMIBC), raising the potential for FGFR inhibitors as a therapy option. Clinical trials of anti-programmed cell death protein 1 (PD1) and anti-PD1 ligand (PD-L1) agents have shown benefit in advanced bladder cancer patients and provided evidence for PD-L1 as a predictive marker. We have assessed the association of FGFR3 mutations with FGFR3 expression, PD-L1 and T-cell infiltrates in MIBC samples.


FGFR3, PD-L1 and CD8 (cytotoxic T-cell marker) expression were assessed by immunohistochemistry (IHC) and FGFR3 mutations by SNaPshot analysis in a cohort of 60 MIBC. FGFR3/FGFR1 expression were also assessed in a cohort of 40 MIBC, 30 NMIBC and 18 normal urothelium (NU) tissues.


FGFR3 expression (H-score >20) was observed in 20% (8/40) of MIBC compared to 60% (23/39) of NMIBC while 94% (17/18) NU were negative. In contrast, FGFR1 expression was low and did not differ between MIBC, NMIBC and NU. FGFR3 mutations were detected in 16% MIBC (10/60) and an association was observed with FGFR3 expression (p 25% cells positive) was 12% (7/59) and immune cell (IC) positivity was 32% (19/59) and FGFR3 mutant samples all displayed low TC PD-L1 (≤5% cells expressing PD-L1) and low CD8 ( 5% cells PDL1 positive) and CD8 from 5-1453 cells/mm2 (23% with > 250 cells/mm2 positive). Consistent with these observations, analysis of the Cancer Genome Atlas MIBC data-set showed FGFR3 mutant/fusion bladder cancers cluster into a low immune subtype.


FGFR3 mutation is associated with increased FGFR3 expression and low PD-L1 and cytotoxic T-cell infiltrates, suggesting these tumours may respond differently to anti-PD1/PD-L1 therapy and supporting investigation of FGFR3 inhibitors as a therapeutic option. Clinical studies with FGFR inhibitors in bladder cancer are ongoing, including assessment of AZD4547 in monotherapy and combination with the anti-PD-L1 agent durvalumab (NCT02546661).

Clinical trial identification

Legal entity responsible for the study





E. Kilgour, H. Angell, N.R. Smith, M. Ahdesmaki, J.C. Barrett, E.A. Harrington: Employee of AstraZeneca and holds stock in AstraZeneca. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings